Mode
Text Size
Log in / Sign up
N/A N=1,410 Randomized Single-blind Screening

Gastroenterology Artificial INtelligence System for Detecting Colorectal Polyps (The GAIN Study)

Colon Adenoma · Colon Polyp · Colon Lesion

Enrolled (actual)
1,410
Serious AEs
0.0%
Results posted
Jan 2025
Primary outcome: Primary: Difference in Adenomas Per Colonoscopy (APC) — 0.60; 0.74 Resected adenomas — p=0.0002

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Computer-Assisted Detection (CADe) Device (Device)
Age
Adult, Older Adult · 45+ yrs
Sex
All
Sponsor
Verily Life Sciences LLC
Primary completion
Oct 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Difference in Adenomas Per Colonoscopy (APC)
0.60; 0.74 0.0002 sig
PRIMARY
Difference in Positive Percent Agreement (PPA)
0.62; 0.56 0.09
SECONDARY
Adenoma Detection Rate (ADR)
38.9; 42.9 0.031 sig
SECONDARY
Number of False Alerts Per Procedure
417
SECONDARY
Mean Withdrawal and Inspection Time (MWT)
8.97; 9.34 0.169
SECONDARY
Polyp Detection Rate (PDR)
364; 425
SECONDARY
Proximal Adenoma Detection Rate (pADR)
198; 236 0.0578
SECONDARY
Flat Adenoma Detection Rate (fADR)
19; 21 0.7813
SECONDARY
Serrated Lesions Per Colonoscopy (SLPC)
0.34; 0.46
SECONDARY
Serrated Lesions Detection Rate (SLDR)
156; 219 0.0004 sig
SECONDARY
Adenoma Detection Rate Including Carcinoma (ADR*)
271; 307 0.1185
SECONDARY
Small Adenoma Detection Rate (sADR)
201; 236 0.0752
SECONDARY
Polyps Per Colonoscopy (PPC)
1.03; 1.32
SECONDARY
Advanced Adenoma Detection Rate (aADR)
60; 59 0.8194
SECONDARY
False Positive Rate (FPR)
0.22; 0.31 0.0008 sig

Summary

This is a prospective, multicenter, randomized controlled study to evaluate the effect of the Computer-Assisted Detection (CADe) Device on Adenomas Per Colonoscopy and Positive Percent Agreement for routine colonoscopies. The control arm is colonoscopy performed with High Definition White Light Endoscopy (HD-WLE) per standard of care. The intervention arm is colonoscopy performed with HD-WLE per standard of care plus the Computer-Assisted Detection (CADe) Device.

Eligibility Criteria

Inclusion Criteria

  • Scheduled to undergo routine screening (including, but not limited to, FIT/Cologuard positive), routine surveillance (≥3 years as scheduled since last colonoscopy), or diagnostic (symptomatic) colonoscopy with High Definition White Light Endoscopy.
  • Between the ages of 45 and 80 years, inclusive
  • Able and willing to provide written informed consent

Exclusion Criteria

  • Self-reported pregnancy
  • Known diagnosis of Colorectal Cancer
  • History of, or referral for, Inflammatory Bowel Disease
  • Previous surgery involving the colon or rectum
  • Referral for known polyp or assessment of post-polypectomy site (i.e. less than 3 years since last colonoscopy).
  • High suspicion or diagnosis of genetic polyposis syndromes, including familial adenomatous polyposis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC), or any other high-risk family history meeting Bethesda guidelines.
  • Referral for overt, symptomatic gastrointestinal bleeding
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05275556). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search